PMID- 22560145 OWN - NLM STAT- MEDLINE DCOM- 20120911 LR - 20211203 IS - 1557-8607 (Electronic) IS - 0889-8561 (Linking) VI - 32 IP - 2 DP - 2012 May TI - The use of intravenous immunoglobulin in autoimmune bullous diseases. PG - 323-30, viii LID - 10.1016/j.iac.2012.04.012 [doi] AB - Intravenous immunoglobulin (IVIG) has been shown to be effective in the treatment of autoimmune blistering diseases and may be an option if disease is refractory to conventional treatment. IVIG effectiveness appears to increase when administered concurrently with a cytotoxic drug and used in multiple treatment cycles (though a single cycle may give benefit). Tapering administration may improve the duration of remission and subcutaneous injections may be an option. This article provides an introduction to the make-up and use of IVIG, and reviews previous studies. CI - Copyright (c) 2012 Elsevier Inc. All rights reserved. FAU - Chee, Shien-Ning AU - Chee SN AD - Department of Dermatology, St George Hospital, Gray Street, Kogarah, Sydney, NSW 2217, Australia. FAU - Murrell, Dedee F AU - Murrell DF LA - eng PT - Journal Article PT - Review DEP - 20120418 PL - United States TA - Immunol Allergy Clin North Am JT - Immunology and allergy clinics of North America JID - 8805635 RN - 0 (Adjuvants, Pharmaceutic) RN - 0 (Immunoglobulins, Intravenous) SB - IM MH - Adjuvants, Pharmaceutic/therapeutic use MH - Animals MH - Autoimmune Diseases/*drug therapy/immunology MH - Clinical Protocols MH - Drug Resistance MH - Humans MH - Immunoglobulins, Intravenous/adverse effects/*therapeutic use MH - Immunosuppression Therapy MH - Skin Diseases, Vesiculobullous/*drug therapy/immunology EDAT- 2012/05/09 06:00 MHDA- 2012/09/12 06:00 CRDT- 2012/05/08 06:00 PHST- 2012/05/08 06:00 [entrez] PHST- 2012/05/09 06:00 [pubmed] PHST- 2012/09/12 06:00 [medline] AID - S0889-8561(12)00027-6 [pii] AID - 10.1016/j.iac.2012.04.012 [doi] PST - ppublish SO - Immunol Allergy Clin North Am. 2012 May;32(2):323-30, viii. doi: 10.1016/j.iac.2012.04.012. Epub 2012 Apr 18.